Skip to main content
Evidence Snapshot

Beta-3 adrenergic receptor

CHEMBL246 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T02:22:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL246
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Beta-3 adrenergic receptor as ChEMBL target CHEMBL246, mapped to UniProt P13945. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Beta-3 adrenergic receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL246
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P13945
Beta-3 adrenergic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Beta-3 adrenergic receptor matters

As of 2026-09-13

Beta-3 adrenergic receptor is reviewed as Beta-3 adrenergic receptor (UniProt P13945); Beta-3 adrenergic receptor shows approved-linked disease relevance led by overactive bladder. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 53 approved drugs, 3161 compounds, and 372 assays, with lead potency reaching pChEMBL 10.8.

Disease context
overactive bladder

Beta-3 adrenergic receptor shows approved-linked disease relevance led by overactive bladder. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include MIRABEGRON, RITOBEGRON, SOLABEGRON.

Start review with overactive bladder because it currently carries approved-linked support. Linked drugs include MIRABEGRON, RITOBEGRON, SOLABEGRON, VIBEGRON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 53 approved drugs, 3161 compounds, and 372 assays for this target. The dominant activity type is EC50. CHEMBL279260 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL279260 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
53 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Beta-3 adrenergic receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P13945, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why overactive bladder is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

3161
Total Compounds
372
Total Assays
53
Approved Drugs
IC50: 898.0, KI: 1222.0, EC50: 1571.0, KD: 78.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL279260
 10.8 EC50 Clinical
No preferred name
CHEMBL1257555
 10.7 EC50 —
No preferred name
CHEMBL446806
 10.5 EC50 —
No preferred name
CHEMBL529659
 10.5 EC50 —
No preferred name
CHEMBL470857
 10.5 EC50 —

Approved Drugs

Structure Compound First Approval
VIBEGRON
CHEMBL2107826
 2018
MIRABEGRON
CHEMBL2095212
 2012
FORMOTEROL
CHEMBL1256786
 2001
CARVEDILOL
CHEMBL723
 1995
SALMETEROL
CHEMBL1263
 1994
PROPAFENONE
CHEMBL631
 1989
LEVOBUNOLOL
CHEMBL1201237
 1985
PINDOLOL
CHEMBL500
 1982
TIMOLOL
CHEMBL499
 1978
PROPRANOLOL
CHEMBL27
 1967
EPINEPHRINE
CHEMBL679
 1965
ISOPROTERENOL
CHEMBL434
 1956
NOREPINEPHRINE
CHEMBL1437
 1950
FENOTEROL
CHEMBL32800
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T02:22:37Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL246